Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors

This study has been completed.
Cancer Research UK
Information provided by (Responsible Party):
Mateon Therapeutics Identifier:
First received: September 14, 2009
Last updated: October 28, 2011
Last verified: October 2011
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):